Evaluation of the immune factors in the tumor environment before and after the treatment of cetuximab combined with chemotherapy

World Journal of Surgical Oncology

Shunchang Jiao²  Junlan Yang²  Xiaoqin Guo¹  Tiefeng Ji²  Fangfang Jing²  Jie Li³  Yanyun Zhu² 

[1] The First Out-patient Department, Bureau of Management and Social Security, Headquarters of the General Logistics Department of PLA, 22 Fuxing Road, Haidian District, Beijing 100842, China;Department of Medical Oncology, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, China;Department of Pathology, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, China

关键词: Clinical efficacy;    Immune state;    Tumor environment;    Chemotherapy;    Cetuximab;   

Others  :  822121
DOI  :  10.1186/1477-7819-11-226

 received in 2013-05-10, accepted in 2013-09-02,  发布年份 2013

【 摘 要 】

Background

The effect of chemotherapy combined with monoclonal antibodies (mAbs) on the immune state of the tumor environment remains unclear and controversial. The aim of this study is to examine the effect of chemotherapy combined with cetuximab (C225, an anti-EGFR mAb) on the immune state of tumor environment, and the correlation of that effect and the clinical efficacy.

Methods

Twelve patients with colorectal cancer, who received the treatment of chemotherapy combined with C225, were enrolled in this study. The tumor specimen of the primary colorectal cancer before and after treatment was obtained. The expression of a series of immune factors (TGF-β1, CD8, IL-2, TNF-α, and VEGF) was measured by immunochemistry. The expression of these immune factors before and after treatment was compared by the Wilcoxon signed-rank test. The correlation of the change of immune parameter expression after treatment and clinical efficacy was examined by chi-square tests. The correlation of the expression of immune factors, clinical efficacy, and treatment number was examined by the Spearman’s correlation analysis.

Results

There was no significant difference between the expression of TGF-β1 before and after the treatment (P >0.05). The change of TGF-β1 expression after treatment significantly correlated negatively with clinical efficacy (P = 0.05). As for CD8, IL-2, VEGF, and TNF-α, there were no significant differences between the expression before and after the treatment (P >0.05), and the change of expression after treatment also did not correlate significantly with clinical efficacy (P >0.05). The change of IL-2 expression after treatment significantly correlated negatively with treatment number (correlation coefficient = -0.585, P = 0.046). The change of TGF-β1 expression after treatment significantly correlated negatively with clinical efficacy (correlation coefficient = -0.684, P = 0.014). Before treatment, the expression of TNF-α significantly correlated positively with the expression of IL-2 (correlation coefficient = 0.629, P = 0.028). After treatment, the expression of TGF-β1 significantly correlated negatively with the expression of CD8 (correlation coefficient = -0.664, P = 0.019).

Conclusions

These results suggested that, in the tumor environment, the change of immune factors after treatment of cetuximab combined with chemotherapy may be associated with clinical efficacy.

【 授权许可】

   
2013 Zhu et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Chew V, Toh HC, Abastado JP: Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol 2012, 2012:608406.
• [2]Callahan MK, Wolchok JD, Allison JP: Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010, 37:473-484.
• [3]Blattman JN, Greenberg PD: Cancer immunotherapy: a treatment for the masses. Science 2004, 305:200-205.
• [4]Buzaid AC, Mathias Cde C, Perazzo F, Simon SD, Fein L, Hidalgo J, Murad AM, Esser R, Senger S, Lerzo G: Cetuximab plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study. Clin Colorectal Cancer 2010, 9:282-289.
• [5]Tahara M, Fujii M: A new horizon in the treatment of head and neck cancer - anti-epidermal growth factor receptor monoclonal antibodies as novel options. Gan To Kagaku Ryoho 2012, 39:2489-2507.
• [6]Derer S, Bauer P, Lohse S, Scheel AH, Berger S, Kellner C, Peipp M, Valerius T: Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies. J Immunol 2012, 189:5230-5239.
• [7]Meyerhardt JA, Heseltine D, Ogino S, Clark JW, Enzinger PC, Ryan DP, Earle CC, Zhu AX, Fuchs CS: Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer 2006, 6:59-65.
• [8]Slovin S: Chemotherapy and immunotherapy combination in advanced prostate cancer. Clin Adv Hematol Oncol 2012, 10:90-100.
• [9]Marr LA, Gilham DE, Campbell JD, Fraser AR: Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies. Clin Exp Immunol 2012, 167:216-225.
• [10]Camus M, Tosolini M, Mlecnik B, Pagès F, Kirilovsky A, Berger A, Costes A, Bindea G, Charoentong P, Bruneval P, Trajanoski Z, Fridman WH, Galon J: Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 2009, 69:2685-2693.
• [11]Bindea G, Mlecnik B, Fridman WH, Galon J: The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol 2011, 33:335-340.
• [12]Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
• [13]Kelly RJ, Morris JC: Transforming growth factor-beta: a target for cancer therapy. J Immunotoxicol 2010, 7:15-26.
• [14]Brand TC, Bermejo C, Canby-Hagino E, Troyer DA, Baillargeon J, Thompson IM, Leach RJ, Naylor SL: Association of polymorphisms in TGFB1 and prostate cancer prognosis. J Urol 2008, 179:754-758.
• [15]Galliher AJ, Neil JR, Schiemann WP: Role of transforming growth factor-beta in cancer progression. Future Oncol 2006, 2:743-763.
• [16]Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limón P: The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010, 10:554-567.
• [17]Barnas JL, Simpson-Abelson MR, Yokota SJ, Kelleher RJ, Bankert RB: T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets. Cancer Microenviron 2010, 3:29-47.
• [18]Jason J, Archibald LK, Nwanyanwu OC, Byrd MG, Kazembe PN, Dobbie H, Jarvis WR: Comparison of serum and cell-specific cytokines in humans. Clin Diagn Lab Immunol 2001, 8:1097-1103.
• [19]Donskov F: Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma. Dan Med Bull 2007, 54:249-265.
• [20]Zloza A, Jagoda MC, Lyons GE, Graves MC, Kohlhapp FJ, O’Sullivan JA, Lacek AT: Nishimura MI, Guevara-Patiño JA. CD8 co-receptor promotes susceptibility of CD8+ T cells to transforming growth factor-β (TGF-β)-mediated suppression. Cancer Immunol Immunother 2011, 60:291-297.